Abstract:

Objective To explore the clinical efficacy of YL⁃1 needle trepanation drainage combined with urokinase injection in the treatment of moderate basal ganglia hemorrhage. Methods We retrospectively analyzed 48 patients with moderate basal ganglia hypertensive cerebral hemorrhage（GCS score 12 ⁃ 15）who were conscious or lethargic with limb and/or speech dysfunction in our hospital from September 2013 to February 2021. The patients received either YL⁃1 needle trepanation drainage combined with urokinase injection（study group）or con⁃ servative treatment（control group）. Differences in time to hematoma elimination，complication rate，and ADL prognosis were analyzed. Results The time to hematoma elimination was（7.50 ± 3.6）days in the study group and （21.14 ± 5.7）days in the control group，and the difference between the two groups was statistically significant （P < 0.05）. There were no statistical differences in the rate of pulmonary infection between the two groups（P > 0.05）. Of the procedure⁃related complications，the incidence was 15.4% for pneumocranium and 3.8% for both intracranial infection and puncture tract bleeding. ADL prognosis assessment one month after the procedure，5 patients were in level Ⅰ，11 in level Ⅱ，8 in level Ⅲ，2 in level Ⅳ，and none in level Ⅴ in the study group；whereas 1 patient in level Ⅰ，4 in level Ⅱ，10 in level Ⅲ，7 in level Ⅳ，and none in level Ⅴ. The difference between the two groups in the number of patients in levels Ⅱ and Ⅳ was statistically significant（P < 0.05）. Conclusions For the treatment of moderate hypertensive cerebral hemorrhage in the basal ganglia area ，YL ⁃ 1 needle trepanation drainage has the advantages of simple operation，minimal invasiveness，faster functional recovery，and better curative effect.

Key words:

YL?1 needle, basal ganglia hemorrhage, urokinase injection